Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K39/215

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20200188508PORCINE EPIDEMIC DIARRHEA VIRUS S PROTEIN AND SUBUNIT VACCINE THEREOF AS WELL AS METHOD FOR PREPARING SUBUNIT VACCINE AND APPLICATION THEREOF
US 18.06.2020
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 16600334 Applicant NOVO BIOTECH CORP. Inventor Hong QIAN

The disclosure discloses a porcine epidemic diarrhea virus S protein and a subunit vaccine thereof as well as a method for preparing the subunit vaccine and application thereof. The vaccine contains 30˜220 μg of a recombinant porcine epidemic diarrhea virus S protein and a pharmaceutically acceptable ISA 201 VG adjuvant. A method for preparing the subunit vaccine comprises the following steps: (1) cloning the recombinant porcine epidemic diarrhea virus S protein; (2) expressing and purifying the recombinant porcine epidemic diarrhea virus S protein; (3) preparing the recombinant porcine epidemic diarrhea virus S protein prepared in (2) into a water phase; (4) emulsifying the water phase and the ISA 201 VG adjuvant in a volume ratio of 46:54 to obtain a vaccine. The vaccine is high in safety, good in immunogenicity, stable in batches, low in production cost and strong in immunogenicity. On the other hand, CHO cell strains suspending and stably and efficiently expressing the PEDV-S protein are successfully constructed and screened for the first time. The CHO cell strain can express the PEDV-S protein in high yield, the yield can reach 1 g/L, and the expressed PEDV-S protein is easy to purify.

2.20200188519REDUCED FOAMING VACCINE COMPOSITIONS
US 18.06.2020
Int.Class A61K 47/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Appl.No 16802089 Applicant Abic Biological Laboratories Ltd. Inventor Noel Yves Henri Jean Genin

The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

3.111254155一种植物作为宿主表达病毒疫苗的方法
CN 09.06.2020
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Appl.No 202010077246.4 Applicant 王跃驹 Inventor 王跃驹
本发明涉及生物技术领域,特别涉及一种植物作为宿主表达2019新型冠状病毒(2019‑nCoV)疫苗的方法。植物作为宿主在表达肺炎2019新型冠状病毒(2019‑nCoV)疫苗中,本发明利用生菜来瞬时表达疫苗以应对2019新型冠状病毒,在较短的时间内(4d)可产生高含量的疫苗蛋白质用于鼻腔喷雾接种或者静脉注射接种。本发明最大限度地减少了生物安全问题,生菜基本不含有植物有毒物质,而且其本身纤维少,利于下游的蛋白纯化。本发明试验结果表明,利用植物如生菜系统生产疫苗可以大大缩短生产周期和生产成本。
4.102119875한국형 중동호흡기증후군 코로나바이러스 감염성 변이 유전자 및 이의 용도
KR 05.06.2020
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No 1020190031225 Applicant 한국화학연구원 Inventor 김성준
본 발명은 한국형 중동호흡기증후군 코로나바이러스의 감염성 변이 유전자와 이의 용도에 관한 것으로, 보다 상세하게는 돌연변이 방법을 이용한, 한국형 중동호흡기증후군 코로나바이러스의 감염성 변이 유전자와 이의 제조방법, 상기 유전자를 포함하는 재조합 벡터에 관한 것이다. 본 발명의 상기 돌연변이 방법을 이용하여 제작한 한국형 중동호흡기증후군 코로나바이러스의 감염성 변이 유전자 및 이의 제조방법은 바이러스 증식 연구와 약독성 바이러스 개발에 유용하게 사용될 수 있다. 또한 상기 유전자를 포함하는 재조합 벡터는 한국형 중동호흡기증후군 코로나바이러스 백신 및 이의 제조방법 관련 기술로 유용하게 사용될 수 있다.
5.111228475用于预防新型冠状病毒的生物制品
CN 05.06.2020
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202010107992.3 Applicant 赛诺(深圳)生物医药研究有限公司 Inventor 张书元
一种用于预防新型冠状病毒(COVID‑19)的生物制品。该生物制品可以为基因疫苗或基因药物,基因疫苗采用E1和E3基因缺失的人5型腺病毒作为载体,搭载表达新型冠状病毒的Spike S1亚单位的S1蛋白抗原或同时搭载表达S1蛋白抗原和N蛋白抗原。藉由抗原蛋白的体内表达激活肌体对新型冠状病毒的免疫反应,达到预防新型冠状病毒感染和传染的效果。
6.111218459一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
CN 02.06.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202010193587.8 Applicant 中国人民解放军军事科学院军事医学研究院 Inventor 陈薇
本发明提供一种以人5型复制缺陷腺病毒为载体的新型冠状病毒疫苗。所述疫苗以E1、E3联合缺失的复制缺陷型人5型腺病毒为载体,以整合腺病毒E1基因的HEK293细胞为包装细胞系,携带的保护性抗原基因是经过优化设计的2019新型冠状病毒(SARS‑CoV‑2)S蛋白基因(Ad5‑nCoV)。S蛋白基因经优化后,在转染细胞中的表达水平显著升高。该疫苗在小鼠和豚鼠模型上均具有良好的免疫原性,能在短时间内诱导机体产生强烈的细胞及体液免疫反应。hACE2转基因小鼠上的保护效果研究显示,单次免疫Ad5‑nCoV14天后能够明显降低肺组织内部的病毒载量,说明该疫苗对2019新型冠状病毒具有良好的免疫保护效果。此外,该疫苗制备快速简便,可在短期内实现大规模生产用于应对突发疫情。
7.111218458编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法
CN 02.06.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202010125774.2 Applicant 珠海丽凡达生物技术有限公司 Inventor 彭育才
本发明提供了一种编码SARS‑CoV‑2病毒抗原的mRNA和疫苗及疫苗的制备方法,涉及疫苗的技术领域。该编码SARS‑CoV‑2病毒抗原的mRNA至少含有编码SARS‑CoV‑2病毒的S蛋白和N蛋白中的至少一个蛋白,和/或至少一个蛋白的片段的编码区,该mRNA递送至体内可以使机体产生免疫反应。
8.111217919一种基于火球菌铁蛋白的新型冠状病毒S蛋白双区域亚单位纳米疫苗
CN 02.06.2020
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No 202010144032.4 Applicant 中山大学 Inventor 张辉
本发明公开了一种基于火球菌铁蛋白的新型冠状病毒S蛋白双区域亚单位纳米疫苗。本发明以病毒的受体结合域(Receptor binding domain,RBD)和融合肽(Fusion peptide,FP)共同作为双抗原,并与火球菌多聚物蛋白(PF_Ferritin)连接组成融和蛋白RBD‑FP‑PF_Ferritin,实现抗原多聚化;再利用真核细胞表达系统表达,可通过PF_Ferritin自组装作用形成二十四聚体纳米抗原。该方案可克服RBD单体免疫原性不足的缺点,所得疫苗能显著的提高宿主针对病毒的中和抗体的水平,产生的抗体具有强力阻挡病毒入侵靶细胞的能力。而且本发明疫苗制备方法简单、易于纯化,安全性高,疫苗可较快的应用于临床试验。
9.111217916猪三种致腹泻病毒中和抗原表位融合蛋白及其构建方法和应用
CN 02.06.2020
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No 202010039900.2 Applicant 扬州大学 Inventor 金文杰
本发明涉及猪三种致腹泻病毒中和抗原表位融合蛋白重构体及其制备方法和应用。所述猪三种致腹泻病毒PEDV、TGEV、PoRV的中和抗原表位融合蛋白的氨基酸序列如SEQ ID NO.2所示。编码该中和抗原表位融合蛋白的基因序列如SEQ ID NO.1所示。本发明分别选取PEDV、TGEV、PoRV的主要中和抗原表位基因并进行拼接,而后通过重组杆状病毒真核表达系统对串联基因进行融合蛋白表达。将表达串联基因融合蛋白的重组病毒通过腹腔注射的方式免疫小鼠,可诱导机体产生免疫应答,具有较强的免疫原性。本发明为预防PEDV、TGEV、PoRV感染提供了一种新的方法,也为猪腹泻病毒新型疫苗的开发奠定了基础。
10.111217918一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒S蛋白双区域亚单位纳米疫苗
CN 02.06.2020
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No 202010144031.X Applicant 中山大学 Inventor 张辉
本发明公开了一种基于2,4‑二氧四氢喋啶合酶的新型冠状病毒S蛋白双区域亚单位纳米疫苗。本发明以病毒的受体结合域(Receptor binding domain,RBD)和融合肽(Fusion peptide,FP)共同作为双抗原,并与来源于Aquifex aeolicus菌株的二氧四氢喋啶合酶多聚物蛋白(Lumazine Synthase,LS)连接组成融和蛋白LS‑RBD‑FP,实现抗原多聚化;再利用真核细胞表达系统表达,可通过LS自组装作用形成六十聚体纳米抗原。该方案可克服RBD单体免疫原性不足的缺点,所得疫苗能显著的提高宿主针对病毒的中和抗体的水平,产生的抗体具有强力阻挡病毒入侵靶细胞的能力。而且本发明疫苗制备方法简单、易于纯化,安全性高,疫苗可较快的应用于临床试验。